SGEN Seattle Genetics, Inc.

76.29-2.07 (-2.64%)
Close: August 23, 2019

Quote

Previous Close
$76.29
Day Range
$75.73-$78.82
52 Week Range
$50.71-$84.37
Volume
495,596
Avg Volume
1,237,052
Dividend TTM
-
Ex-Dividend Date
-

Valuation

Market Cap
$12.88B
Enterprise Value (EV)
$12.82B
PE Ratio
-
EV/EBITDA
-54.80
Price/Sales
20.21
Price/Book
10.11
PEG Ratio
0.21

Financials

Revenue
$654.70M
Gross Profit
$566.41M
EBITDA
-$233.97M
EPS, ttm
-$1.74
Profit Margin
-
Revenue/Employee
$502.84K
Next Earnings Date
11/4/2019 (71 days)
Debt to Equity
-
Debt
$349.55M
Cash
$410.67M
Net Debt
-

Performance

Beta
1.49
200 Day Moving Avg
$68.87
50 Day Moving Avg
$72.89
52 Week Change
2.28%
YTD Change
30.06%
1 Month Change
3.70%
3 Month Change
10.34%
6 Month Change
4.94%
1 Year Change
2.28%
2 Year Change
13.46%
5 Year Change
100.06%

Share Count

Shares Outstanding
168.9M
Float
166.6M
Restricted Shares
2.2M
Restricted Shares, %
1.33%

Seattle Genetics, Inc. Company Details

Sector: Health Technology

Industry: Biotechnology

CEO: Clay B. Siegall

Website: http://www.seattlegenetics.com

Description: Seattle Genetics, Inc. is a biotechnology company, which engages in the development and commercialization of antibody-based therapies for the treatment of cancer. Its product Adcetris is an antibody-drug for the treatment of lymphoma. The firm is also advancing a pipeline of novel therapies for solid tumors and blood-related cancers. The company was founded by Clay B. Siegall and H. Perry Fell on July 15, 1997 and is headquartered in Bothell, WA.

Employees: 1,302